IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment

Table 4

Diagnostic parameters of patients in stage F0 vs. F1–4.

Parameter	Genotype	Cut-off	Sensitivity	95% CI	Specificity	95% CI
Anti-GlcNAcβ	1b	0.334	0.59	0.39–0.78	0.84	0.64–0.95
ALP	1b	74.5	0.64	0.41–0.83	0.76	0.50–0.93
	1b and 3a	72.5	0.64	0.45–0.80	0.77	0.56–0.91